Interestingly, the effects of LY2405319 (LY), an engineered FGF21 variant [36, 37], in a randomized, placebo-controlled, double-blind proof-of-concept trial on 46 patients with obesity and type 2 diabetes has been recently reported. The gene discussed is FGF21; the disease is obesity disorder.